[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.226.244.70. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Research Letter
Dec 2012

Efficacy and Safety of Tumor Necrosis Factor Inhibitors in Acute Generalized Pustular Psoriasis

Author Affiliations

Author Affiliations: Sorbonne Paris Cité Université Paris Diderot, Assistance Publique-Hôpitaux de Paris, Service de Dermatologie, Hôpital Saint-Louis, Paris, France (Drs Viguier, Pagès, Rybojad, and Bachelez); Université de Franche Comté, EA 3181, IFR 133, and Dermatologie, Centre Hospitalier Universitaire (CHU), Besançon, France (Dr Aubin); Université Lille 2, Dermatologie, Centre Hospitalier Régional Universitaire, Lille, France (Dr Delaporte); Université Paul Sabatier, Dermatologie, Hôpital Larrey, CHU, Toulouse, France (Dr Paul); Université Bordeaux 2, EA 2406 et Service de Dermatologie, Hôpital Haut-Lévequê, CHU, Bordeaux, France (Dr Beylot-Barry); Immunologie Clinique, Centre Hospitalier Lyon-Sud, Lyon, France (Dr Goujon); Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie, Paris (Drs Viguier, Aubin, Paul, Beylot-Barry, Goujon, and Bachelez); and Institut National de la Santé Et de la Recherche Médicale (INSERM) U781, Hôpital Necker-Enfants Malades, Paris (Dr Bachelez).

Arch Dermatol. 2012;148(12):1423-1425. doi:10.1001/2013.jamadermatol.80

Acute generalized pustular psoriasis (GPP) is a rare, life-threatening form of psoriasis; therefore, rapidly effective treatment is needed. Etanercept was beneficial in GPP,1 but the benefit of infliximab or adalimumab was less frequently reported.2 The purpose of the present study was to evaluate the efficacy and safety of tumor necrosis factor (TNF) inhibitors in a series of patients with GPP.

A national, multicenter, retrospective study was conducted among patients who were seen in French university hospital dermatology departments and who received TNF inhibitors for GPP flaring within the postlabeling period. The study received approval from the institutional review board (Comité d’Evaluation de l’Ethique des projets de Recherche Biomédicale, Paris Nord, No. 12-017).

×